Willis H. Navarro, M.D., has served as Vice President, Clinical Development at Nurix since September 2024. Dr. Navarro is trained as a hematologist/oncologist/marrow transplant physician and has more than 15 years of experience in drug development and clinical trials. Prior to joining Nurix, Dr. Navarro held senior leadership positions at Aadi Bioscience, Atara Biotherapeutics, NMDP (National Marrow Donor Program), and Genentech, and was an academic physician at the University of California, San Francisco (UCSF). Currently, Dr. Navarro is a Clinical Professor of Medicine at the University of Arizona Cancer Center. Dr. Navarro holds a BA in Chemistry from Brown University, and an MD from UCSF.

Michael Roth has served as Vice President of Quality at Nurix since May 2024.  Mr. Roth has over 30 years of pharmaceutical experience overseeing all aspects of quality assurance and compliance, as well as extensive experience managing PAI/BIMO inspections and commercial activities. Prior to joining Nurix, Mr. Roth served as Vice President of Quality Assurance at Rain Oncology, where he managed the quality groups and supported the company’s clinical and non-clinical studies.  Previously, he served as Vice President of Quality Assurance at Principia Biopharma, Executive Director of Quality Assurance at Rigel Pharmaceuticals, and Director of Quality Control and Assurance at Zosano Pharma. He has collaborated on three drugs that received FDA approval. Mr. Roth holds a B.A. in Chemistry from the State University College of Buffalo and an M.A. in Pharmacology from the State University of New York at Buffalo (RPMI). 

Marine Champsaur, Ph.D., has served as Vice President and Head of Medical Affairs since August 2022. Prior to joining Nurix, Dr. Champsaur provided scientific strategy and communications consulting services to early-stage biotech companies across a range of treatment modalities spanning the autoimmune and inflammatory disease, vaccine, and oncology space. Before that, Dr. Champsaur played a pivotal role in building the medical affairs function at Dermira, Inc., where she led the medical strategy and communications team. Early in her career, she held roles of increasing responsibility at UCB Pharma within immunology global medical affairs. Dr. Champsaur holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley, and a Ph.D. in Immunology from the University of California, San Francisco.

Linda L. Neuman, M.D., M.B.A., has served as Vice President of Clinical Development at Nurix since May 2024.  Dr. Neuman is trained as an internist, practiced medicine for 10 years prior to entering industry, and has more than 12 years of drug development experience in both oncology and rare disease. Prior to joining Nurix, she held senior positions in clinical development at Aeglea BioTherapeutics, Catalyst Biosciences, Adverum Biotechnologies, Sunesis Pharmaceuticals, Puma Biotechnology, and Onyx Pharmaceuticals.  Dr. Neuman completed her internal medicine residency at St. Vincent’s Hospital in Indianapolis.  She holds a B.S. in Biology from Southern Illinois University at Edwardsville, an M.B.A from Indiana Wesleyan University, and an M.D from Southern Illinois University.

Joseph D. Robinson has served as Vice President, Facilities Operations at Nurix since July 2023. Mr. Robinson has been responsible for developing the facilities, real estate, lab services and operations functions at Nurix since he joined the company in January 2016. Prior to Nurix, Mr. Robinson served in positions of increasing responsibility developing and growing administrative and operational functions for early-stage companies, including Presidio Pharmaceuticals, a developer of anti-viral therapeutics, and VaxGen, a vaccine company. Mr. Robinson began his career at the Conant Medical Group. Mr. Robinson studied Communications at San Francisco State University and Management at St. Mary’s College of California.  

John M. Lin has served as Vice President, Research Informatics at Nurix since July 2024 and served as the company’s Executive Director, Research Informatics from May 2021 through June 2024.  Prior to joining Nurix, he served in multiple roles in Data Science, Systems, and Infrastructure at Nektar Therapeutics, Five Prime Therapeutics and Novartis.  Mr. Lin holds a B.S. in Electrical and Computer Engineering from the University of California, Berkeley, and an M.S. in Biomedical Engineering from Columbia University.  

Hao Lu, Ph.D., joined Nurix Therapeutics in July 2021 and has served as Vice President of Discovery Pharmacology since July 2024. With over 15 years of experience in drug discovery for small molecules and biologics, Dr. Lu has played a key role in advancing therapeutic candidates across a range of areas, including oncology, immune-oncology, immunology, and infectious diseases. Before joining Nurix, he held position at EMD Serono and Bristol-Myers Squibb. Dr. Lu earned his B.S. in Chemistry from The Chinese University of Hong Kong, graduating with first-class honors, and his Ph.D. in Biochemistry and Chemical Biology from Stony Brook University.

Eva Kras, M.S., joined Nurix in 2023 and has served as Vice President and Head of Regulatory Affairs since February 2024. Ms. Kras has over 22 years of experience in drug development, spanning early to late-stage programs across several therapeutic areas, including oncology/hematology and rare disease. Throughout her career, she has been responsible for developing innovative regulatory strategies leading to numerous global regulatory marketing approvals. Prior to joining Nurix, she held a variety of roles at Amgen, Seattle Genetics, BioMarin, GSK, Coherus and most recently BeiGene. Ms. Kras earned her B.S. in Pharmacology from the University of California, Santa Barbara, and her M.S. in Regulatory Science from the USC School of Pharmacy.

Eren Demirhan, Ph.D., has served as Vice President and Head of Biometrics at Nurix since March 2021, leading the Company’s Biostatistics and Clinical Data Science efforts. Dr. Demirhan brings over 17 years of experience in drug pharmaceuticals and biotechnology, championing data-driven drug development ideology and implementation. Prior to joining Nurix, Dr. Demirhan served in a variety of roles at Allogene Therapeutics, Medivation, Onyx Pharmaceuticals, Novartis, Biogen, and GSK. Dr. Demirhan holds a B.A. in Statistics from Middle East Technical University, a Ph.D. in Statistics from North Carolina State University and an M.B.A from Kenan Flagler Business School, University of North Carolina – Chapel Hill.

Elizabeth Bosch, Ph.D., has served as Vice President, Alliance and Program Management at Nurix since January 2023 and served as the company’s Head of Alliance Management and Research Program Management from June 2018 through December 2022. Prior to joining Nurix, she worked at Five Prime Therapeutics, Inc., Incyte Corporation and Sentinel Biosciences, Inc. Dr. Bosch earned an M.S. and Ph.D. from the University of California, Los Angeles and completed her postdoctoral work at the Cell Signaling Dept, DNAX/Schering Plough Biopharma and the Jules Stein Eye Institute at UCLA.